Cancer Cell International

Table 2 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with Herceptin® and Doxorubicin in gastric cancer cell lines

From: Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines

YBC-2	Combination Index Value			Parameter (μM)
Drug	ED50	ED75	ED90	Dm	m	r
DOX				2.93	0.54	0.98
HER				1201.02	0.32	0.91
DOX + HER	0.09	0.05	0.03	0.25	0.74	0.96
Diagnosis combined effect	synergy	synergy	synergy
YBC-3	Combination Index Value			Parameter (μM)
Drug	ED50	ED75	ED90	Dm	m	r
DOX				2.310	0.768	0.946
HER				46.063	0.623	0.970
DOX + HER	0.266	0.598	1.377	0.406	0.469	0.925
Diagnosis combined effect	synergy	synergy	antagonism
NCI-N87	Combination Index Value			Parameter (μM)
Drug	ED50	ED75	ED90	Dm	m	r
DOX				0.070	0.398	0.864
HER				113350	0.191	0.635
DOX + HER	0.005	0.004	0.003	0.000	0.437	0.995
Diagnosis combined effect	synergy	synergy	synergy
U-87 MG	Combination Index Value			Parameter (μM)
Drug	ED50	ED75	ED90	Dm	m	r
DOX				0.295	0.620	0.997
HER				1845.5	0.457	0.860
DOX + HER	0.441	0.435	0.448	0.101	0.589	0.992
Diagnosis combined effect	synergy	synergy	synergy
SK-BR-3	Combination Index Value			Parameter (μM)
Drug	ED50	ED75	ED90	Dm	m	r
DOX				0.103	0.832	0.998
HER				1424000	0.046	0.435
DOX + HER	0.046	0.074	0.117	0.005	0.616	0.985
Diagnosis combined effect	synergy	synergy	synergy

DOX, Doxorubicin; HER, Herceptin.

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com